Cancer cells metabolism differs significantly from the original tissue from which they originate. Cancer cells proliferate more rapidly than normal healthy cells and adapt their metabolism to drive a faster formation of various cellular components such as nucleotides, amino acids, and lipids.
Cancer cells also create an environment in the tumor that favors their own survival at the expense of the body’s healthy cells. The environment in the tumor becomes acidic and has a lower concentration of oxygen and nutrients, which makes it more difficult for the body’s own cells to survive. This also makes it harder for the body’s immune cells to do their job, and the body’s natural protection against cancer is weakened.
Changed metabolism is crucial for the ability of cancer cells to spread to other parts of the body, which enables development of cancer therapies that not only reduce the growth of existing tumors but also reduce the risk of the appearance of daughter tumors, e.g. metastasis.
By attacking the metabolic processes in the tumor we can fight cancer on several fronts; partly reducing the growth of cancer cells, recreating a better balance in the tumor’s micro environment, reducing the risk of cancer spreading to other parts of the body and last but not least, strengthening the body’s own immune system.
Tumor metabolism is a therapeutic area that has attracted significant interest lately and a large number of global pharmaceutical companies are interested in the area. At Sprint Bioscience, we work long-term in expanding and strengthening our expertise in this area to become an obvious partner for companies that want to be leaders in the field.
Diabetes is caused by a metabolic shift of the cells where insulin sensitivity has deteriorated. This leads to elevated blood sugar despite high insulin levels. The cause of the high blood sugar is partly decreased sugar uptake in muscle cells, partly increased excretion of sugar from the liver. Today’s therapies have limited efficacy and therefore there is still a great need for new drugs for type 2 diabetes.